Search Result

Results for "

Aβ1-42

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Amyloid-β (62) Apoptosis (5) Autophagy (1) Beta-secretase (3) Chemerin Receptor (3) Cholinesterase (ChE) (27) ERK (2) Ferroptosis (2) GSK-3 (4) HDAC (3) Histamine Receptor (1) JNK (1) Keap1-Nrf2 (1) mAChR (1) Mitochondrial Metabolism (1) MMP (1) Monoamine Oxidase (6) NF-κB (3) NOD-like Receptor (NLR) (1) Potassium Channel (1) Reactive Oxygen Species (4) ROS Kinase (1) Tau Protein (5) α-synuclein (1) γ-secretase (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (3) Inflammation/Immunology (8) Metabolic Disease (1) Neurological Disease (82)
Click Chemistry:	Alkynes (2)

Inhibitors & Agonists

Peptides

Natural
Products

Click Chemistry

Targets Recommended: Ack1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150003

Aβ1–42 aggregation inhibitor 1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Aβ1-42 aggregation inhibitor 1 inhibits AChE (acetylcholinesterase) and BuChE (butyrylcholinesterase) with the IC₅₀ value of 2.64 μM and 1.29 μM, respectively. Aβ1-42 aggregation inhibitor 1 inhibits self-mediated Aβ1-42 aggregation by 51.29% at a concentration of 25 μM. Aβ1-42 aggregation inhibitor 1 has the potential for the research of anti-Alzheimer's disease .

HY-105252A

BF 227	Amyloid-β	Neurological Disease
BF 227 is a candidate for an amyloid imaging probe for PET, with a K_i of 4.3 nM for Aβ1-42 fibrils.

HY-162093

Aβ1–42 aggregation inhibitor 2	Amyloid-β	Neurological Disease
Aβ1–42 aggregation inhibitor 2 (compound 7c) is a potent inhibitor of Aβ1-42 aggregation that plays an important role in Alzheimer's disease research. Aβ1–42 aggregation inhibitor 2 displays excellent antioxidant, metal ions chelating, oxidative stress alleviation, neuroprotective and anti-neuroinflammatory activities .

HY-P3908

FITC-β-Ala-Amyloid β-Protein (1-42) (ammonium)	Amyloid-β	Neurological Disease
FITC-β-Ala-Amyloid β-Protein (1-42) ammonium is a FITC tagged Aβ1-42 monomer peptide. Aβ1-42 plays a key role in the pathogenesis of Alzheimer’s disease .

HY-144388

ChE/Aβ1-42-IN-1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
ChE/Aβ1-42-IN-1 (compound 28) is a potent ChE and Aβ_1-42 aggregation inhibitor with IC₅₀s of 0.062, 0.767 and 1.227 µM for AChE, BuChE and Aβ_1-42 aggregation, respectively. ChE/β1-42-IN-1 shows excellent BBB penetration. ChE/Aβ1-42-IN-1 is a potent multi-targeted anti-Alzheimer's agent .

HY-144324

AChE-IN-6	Cholinesterase (ChE)	Neurological Disease
AChE-IN-6 (Compound 12a) is an optimal multifunctional ligand with significant inhibition of AChE (EeAChE, IC₅₀ = 0.20 μM; HuAChE, IC₅₀ = 37.02 nM) and anti-Aβ activity (IC₅₀ = 1.92 μM for self-induced Aβ1-42 aggregation; IC₅₀ = 1.80 μM for disaggregation of Aβ1-42 fibrils; IC₅₀ = 2.18 μM for Cu2+-induced Aβ1-42 aggregation; IC₅₀ = 1.17 μM for disaggregation of Cu2+-induced Aβ1-42 fibrils). AChE-IN-6 has the potential for the research of Alzheimer's disease .

HY-148547

q-FTAA	Amyloid-β	Neurological Disease
q-FTAA binds to Aβ1-42 fibrils with EC₅₀ values of 330-630, 300-500 nM for Aβ1-42 fibrils, alzheimer's disease PIB binding complex (ADPBC) , respectively. q-FTAA has the potential for the research of Alzheimer's disease (AD) .

HY-144327

Aβ-IN-2	Amyloid-β	Neurological Disease
Aβ-IN-2 is a Aβ1–42 aggregation inhibitor. Aβ-IN-2 inhibits Aβ1-42 self-aggregation in vitro by delaying the exponential growth phase or reduces the quantity of fibrils in the steady state. Aβ-IN-2 can be used for the research of conformational disorders .

HY-144326

Aβ-IN-1	Amyloid-β	Neurological Disease
Aβ-IN-1 is a Aβ1–42 aggregation inhibitor. Aβ-IN-1 inhibits Aβ1-42 self-aggregation in vitro by delaying the exponential growth phase or reduces the quantity of fibrils in the steady state. Aβ-IN-1 can be used for the research of conformational disorders .

HY-14535

SEN-1269	Amyloid-β	Neurological Disease
SEN-1269 is a potent Aβ aggregation inhibitor. SEN-1269 blocks Aβ(1-42) aggregation and protects neuronal cell lines exposed to Aβ(1-42). SEN-1269 reduces the deficits in LTP and memory induced by Aβ oligomers. SEN-1269 can be used for the research of Alzheimer's disease .

HY-141661

Aβ/tau aggregation-IN-1	Amyloid-β	Neurological Disease
Aβ/tau aggregation-IN-1 is a potent Aβ_1-42 β-sheets formation and tau aggregation inhibitor. The K_D values of Aβ/tau aggregation-IN-1 with Aβ_1-42 and tau are 160 μM and 337 μM, respectively. Aβ/tau aggregation-IN-1 can permeate the blood-brain barrier .

HY-P4886A

Amyloid β-Protein (3-42) TFA	Amyloid-β	Neurological Disease
Amyloid β-Protein (3-42) TFA is a precursor of Pyr peptide. Pyroglutamic acid-modified Aβ (pEAβ) (3-42) is the core of the amyloid plaque in Alzheimer's disease. pEAβ (3-42) accelerates the aggregation of Aβ(1-42), while Aβ(1-42) significantly slows down the primary and secondary nucleation of pEAβ(3-42).

HY-112830

BF-168	Amyloid-β	Neurological Disease
BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a K_i of 6.4 nM for Aβ1-42.

HY-P4886

Amyloid β-Protein (3-42)	Amyloid-β	Neurological Disease
Amyloid β-Protein (3-42) is the precursor of Pyr peptide. Pyroglutamate-modified Aβ (pEAβ) (3-42) is the core of the amyloid template block in Alzheimer's disease. pEAβ(3-42) accelerated the aggregation of Aβ(1-42), while Aβ(1-42) significantly slowed the primary and secondary nucleation of pEAβ(3-42) .

HY-160831

PQQ-trimethylester PQQ-TME	α-synuclein	Neurological Disease
PQQ-trimethylester (PQQ-TME) is a synthetic compound that is a trimethylester derivative of pyrroloquinoline quinone (PQQ). PQQ-trimethylester has twice the blood-brain barrier permeability of PQQ (HY-100196) in vitro. In addition, PQQ-trimethylester shows strong inhibitory activity against α-synuclein, amyloid β1-42 (Aβ1-42) and prion protein fibrillation. PQQ-trimethylester can be used in the study of neurodegenerative diseases .

HY-P1051

β-Amyloid (12-28) Amyloid β-Protein (12-28)	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research .

HY-144389

hAChE/Aβ1-42-IN-1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
hAChE/Aβ1-42-IN-1 (Compound 16) is a potent inhibitor of hAChE and Aβ1-42 aggregation. hAChE/Aβ1-42-IN-1 shows acceptable relative safety upon hepG2 cell line and excellent BBB penetration with wide safety margin. hAChE/Aβ1-42-IN-1 has the potential for the research of Alzheimer disease (AD) .

HY-152506

Antioxidant agent-8	Amyloid-β	Neurological Disease
Antioxidant agent-8 is an orally active inhibitor of Aβ_1-42 deposition. Antioxidant agent-8 inhibits fibril aggregation (IC₅₀=11.15 µM) and promotes fibril disaggregation (IC₅₀=6.87 µM). Antioxidant agent-8 also inhibits Cu ²⁺-induced Aβ_1-42 fibril aggregation (IC₅₀=3.69 µM) and promotes Cu ²⁺-induced Aβ_1-42 fibril disaggregation (IC₅₀=3.35 µM). Antioxidant agent-8 has antioxidant activity, anti-inflammatory activity, biosafety, blood-brain barrier permeability and neuroprotective effect .

HY-P1051A

β-Amyloid (12-28) (TFA) Amyloid β-Protein (12-28) (TFA); Amyloid Beta-Peptide (12-28) (human) TFA; β-Amyloid protein fragment(12-28) TFA	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (TFA) (Amyloid β-Protein (12-28) (TFA)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) (TFA) shows aggregation properties. β-Amyloid (12-28) (TFA) has the potential for Alzheimer’s disease research .

HY-P1787

β-Amyloid (4-10)	Amyloid-β	Neurological Disease
β-Amyloid (4-10) is an epitope for the polyclonal anti-Aβ(1-42) antibody, reduces amyloid deposition in a transgenic Alzheimer disease mouse model .

HY-P1060

LPYFD-NH2	Amyloid-β	Neurological Disease
LPYFD-NH2, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 can be used for the research of Alzheimer’s disease .

HY-P1060A

LPYFD-NH2 TFA	Amyloid-β	Neurological Disease
LPYFD-NH2 TFA, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 TFA can be used for the research of Alzheimer’s disease .

HY-149430

YIAD-0205	Amyloid-β	Neurological Disease
YIAD-0205 is an orally available Aβ(1?42) aggregation inhibitor. YIAD-0205 demonstrated in vivo efficacy in an AD transgenic mouse model with five familial AD mutations (5XFAD) .

HY-W265961

Squoxin ST1859; 1,1′-Methylenedi-2-naphthol	Amyloid-β	Neurological Disease Inflammation/Immunology
Squoxin (ST1859) is an antiamyloid agent that specifically binds to Aβ1-42 and prevents the aggregation and fibril formation of Aβ. Squoxin crosses the blood-brain barrier (BBB) and has anthelmintic activity and anti-inflammatory properties .

HY-117957

BMS-932481	γ-secretase	Neurological Disease
BMS-932481 is an orally active modulator for γ-secretase, selectively reduce Aβ1-42 and Aβ1-40 production, with IC₅₀s of 6.6 and 25.3 nM, respectively .

HY-N0602

Ginsenoside Rg2 3 Publications Verification Chikusetsusaponin I; Panaxoside Rg2; Prosapogenin C2	NF-κB Amyloid-β	Cardiovascular Disease Neurological Disease Cancer
Ginsenoside Rg2 is one of the major active components of ginseng. Ginsenoside Rg2 inhibits VCAM-1 and ICAM-1 expressions stimulated with lipopolysaccharide (LPS). Ginsenoside Rg2 also reduces Aβ_1-42 accumulation.

HY-N1431A

Tabersonine hydrochloride	Amyloid-β	Neurological Disease Inflammation/Immunology
Tabersonine hydrochloride is an indole alkaloid mainly isolated from Catharanthus roseus. Tabersonine disrupts Aβ(1-42) aggregation and ameliorates Aβ aggregate-induced cytotoxicity. Tabersonine has anti-inflammatory activities and is a potential therapeutic candidate for the treatment of ALI/ARDS .

HY-N1431

Tabersonine 1 Publications Verification	Amyloid-β	Neurological Disease Inflammation/Immunology
Tabersonine is an indole alkaloid mainly isolated from Catharanthus roseus. Tabersonine disrupts Aβ(1-42) aggregation and ameliorates Aβ aggregate-induced cytotoxicity. Tabersonine has anti-inflammatory activities and acts as a potential therapeutic candidate for the treatment of ALI/ARDS .

HY-128346

PQM130	Amyloid-β	Neurological Disease
PQM130, a Feruloyl-Donepezil Hybrid compound with brain penatration, is a multitarget agent candidate against the neurotoxicity induced by Aβ_1-42 oligomer (AβO) and shows anti-inflammatory activity. PQM130 acts as a neuroprotective compound for anti-AD agent development .

HY-P10578

SEN 304	Amyloid-β	Neurological Disease
SEN 304 is an Aβ aggregation inhibitor. SEN 304 can bind directly to Aβ(1-42), delay β-sheet formation and promote aggregation of toxic oligomers into a nontoxic form. SEN 304 can be used for research of Alzheimer’s disease .

HY-N3562

Cedrin	Reactive Oxygen Species	Neurological Disease
Cedrin is a natural flavonoid that can be found in Cedrus deodara. Cedrin protects PC12 cells against neurotoxicity induced by Aβ1-42. Cedrin can reduce reactive oxygen species overproduction, increase the activity of superoxide dismutase and decrease malondialdehyde content .

HY-162339

BChE-IN-30	Cholinesterase (ChE)	Neurological Disease
BChE-IN-30 (compound (R)-37a) is a BChE inhibitor (IC₅₀: 5 nM) with anti-inflammatory activity and low toxicity. BChE-IN-30 can improve cognitive deficits induced by scopolamine and Aβ1-42 peptide and can be used in the study of late-stage AD .

HY-P10630

Pep63	Amyloid-β	Neurological Disease
Pep63 is a neuroprotective peptide (VFQVRARTVA). Pep63 has a neuroprotective effect on synaptic plasticity and memory. Pep63 can competitively bind with Aβ1-42 oligomers, and can block Aβ fiber formation. Pep63 can be used for Alzheimer’s disease (AD) research .

HY-N0249

Saikosaponin C	Amyloid-β	Neurological Disease
Saikosaponin C is a bioactive component found in radix bupleuri, targets amyloid beta and tau in Alzheimer's disease. Saikosaponin C inhibits the secretion of both Aβ1-40 and Aβ1-42, and suppresses abnormal tau phosphorylation, but shows no effect on BACE1 activity and expression .

HY-161674

Monoamine Oxidase B inhibitor 4	Monoamine Oxidase	Neurological Disease
Monoamine Oxidase B inhibitor 4 (compound 1l) is a selective inhibitor of human monoamine oxidase-B (hMAO-B) (IC50=8.3 nM). Monoamine Oxidase B inhibitor 4 also has anti-neuroinflammatory and low neurotoxicity. Monoamine Oxidase B inhibitor 4 can inhibit the release of NO, TNF-α and IL-1β stimulated by LPS and Aβ1-42, and can also attenuate Aβ(1-42)-induced cytotoxicity .

HY-162812

H3R antagonist 4	Apoptosis Cholinesterase (ChE) Tau Protein Ferroptosis Histamine Receptor	Neurological Disease
H3R antagonist 4 (compound 11L) was a dual inhibitor of cholinesterase and histamine receptor (H3R), with corresponding IC₅₀ of 7.04 μM (eeAChE), 9.73 μM (hAChE)(reversible) and 1.09 nM (H3R) , respectively. H3R antagonist 4 inhibited the aggregation of Aβ_1-42 induced by itself and Cu ²⁺ (95.48% and 88.63%) , and degraded the Aβ_1-42 fibrils induced by itself and Cu ²⁺ (80.16% and 89.30%) . H3R antagonist 4 chelate biometals such as Cu ²⁺, Zn ²⁺, Al ³⁺, and Fe ²⁺. H3R antagonist 4 significantly reduced tau protein hyperphosphorylation induced by Aβ_1-42 and inhibited RSL-3-induced apoptosis and ferroptosis in PC12 cells. H3R antagonist 4 had the best blood-brain barrier permeability and intestinal absorption in hCMEC/D3 and hPepT1-MDCK cells.H3R antagonist 4 ameliorates learning and memory impairment in a mouse model of Alzheimer's disease induced by scopolamine (HY-N0296) .

HY-157978

AChE-IN-59	Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE-IN-59 (compounds 3b) is an AChE inhibitor, with an IC₅₀ value of 0.05 μM. AChE-IN-59 can inhibit the aggregation of Aβ1-42, protect nerve cells and penetrate the blood-brain barrier well. AChE-IN-59 can be used for the research of Alzheimer's disease (AD) .

HY-P3860

Biotinyl-Amyloid β-Protein (1-42) (ammonium)	Amyloid-β	Neurological Disease
Biotinyl-Amyloid β-Protein (1-42) ammonium is a biotinylated Amyloid β-Protein (1-42) (HY-P1363). Biotinyl-Amyloid β-Protein (1-42) ammonium can be used for the research of Aβ1-42 converts to Aβ1-40 in brain .

HY-P10823

RI-OR2	Amyloid-β	Neurological Disease
RI-OR2, a retro-inverso peptide, is an amyloid-β (Aβ) oligomerization inhibitor. RI-OR2 binds to immobilized β-Amyloid (1-42) (HY-P1363A) monomers and fibrils, with an apparent K_d of 9-12 μM, and also acted as an inhibitor of Aβ(1-42) fibril extension .

HY-W748591

Cannflavin A	Apoptosis Amyloid-β	Cancer
Cannflavin A can be isolated from Cannabis sativa L. Cannflavin A has anti-cancer, neuroprotective and anti-inflammatory activity. Cannflavin A inhibits Aβ1-42 aggregation. Cannflavin A also inhibits kynurenine-3-monooxygenase (KMO). Cannflavin A activates apoptosis via caspase-3 cleavage .

HY-136736

β-Secretase Inhibitor II	Beta-secretase	Neurological Disease
β-Secretase Inhibitor II is a β-Secretase inhibitor. β-Secretase Inhibitor II is a simple tripeptide aldehyde (IC₅₀=700 nM for inhibition of total Aβ and IC₅₀=2.5 μM for Aβ_1–42). β-Secretase Inhibitor II can be used for the research of Alzheimer's disease .

HY-N0602R

Ginsenoside Rg2 (Standard) Chikusetsusaponin I(Standard); Panaxoside Rg2(Standard); Prosapogenin C2 (Standard)	NF-κB Amyloid-β	Cardiovascular Disease Neurological Disease Cancer
Ginsenoside Rg2 (Standard) is the analytical standard of Ginsenoside Rg2. This product is intended for research and analytical applications. Ginsenoside Rg2 is one of the major active components of ginseng. Ginsenoside Rg2 inhibits VCAM-1 and ICAM-1 expressions stimulated with lipopolysaccharide (LPS). Ginsenoside Rg2 also reduces Aβ_1-42 accumulation.

HY-N1876

Aromadendrane-4β,10α-diol	Others	Neurological Disease
Aromadendrane-4β,10α-diol is a sesquiterpene alcohol. Aromadendrane-4β,10α-diol significantly ameliorates the Aβ1-42 peptide-induced memory impairment. Aromadendrane-4β,10α-diol can be used for Alzheimer's disease (AD) research .

HY-146314

MAO-B-IN-9	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent MAO-B (monoamine oxidase B) inhibitor, with an IC₅₀ of 0.18 μM. MAO-B-IN-9 prevents Aβ_1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ_1-42 anti-aggregation effects . MAO-B-IN-9 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-155366

hAChE-IN-6	Cholinesterase (ChE) GSK-3	Neurological Disease
hAChE-IN-6 (compound 51) is a brain penetrant AChE inhibitor with an IC₅₀ of 0.16 μM. hAChE-IN-6 also inhibits hBuChE and GSK3β with IC₅₀ values of 0.69 μM and 0.26 μM, respectively. hAChE-IN-6 inhibits tau protein and Aβ1-42 self-aggregation, and can be used for Alzheimer's disease (AD) research .

HY-149984

MAO-B-IN-21	Monoamine Oxidase	Neurological Disease Inflammation/Immunology
MAO-B-IN-21 is an excellent MAO-B inhibitor with antioxidant activity and anti-Aβ aggregation activity. MAO-B-IN-21 also exhibits metal-ion chelating ability, anti-neuroinflammation (NO, TNF-α), neuroprotective activity and BBB permeability. MAO-B-IN-21 significantly improves the memory and cognitive impairment in Aβ1-42 induced Alzheimer's disease mice model .

HY-157382

AChE-IN-51	Cholinesterase (ChE) Amyloid-β MMP	Neurological Disease
AChE-IN-51 (compound 8C) is an orally active, non-competitive inhibitor of AChE and BChE (IC₅₀: 84 nM, 97 nM). It also inhibits MMP-2 and amyloid Aβ_1-42 aggregates (IC₅₀: 724 nM, 302 nM). AChE-IN-51 has low cytotoxicity and in silico predicted blood-brain barrier permeability. Can be used for research on diseases such as Alzheimer's disease (AD) .

HY-N0249R

Saikosaponin C (Standard)	Amyloid-β	Neurological Disease
Saikosaponin C (Standard) is the analytical standard of Saikosaponin C. This product is intended for research and analytical applications. Saikosaponin C is a bioactive component found in radix bupleuri, targets amyloid beta and tau in Alzheimer's disease. Saikosaponin C inhibits the secretion of both Aβ1-40 and Aβ1-42, and suppresses abnormal tau phosphorylation, but shows no effect on BACE1 activity and expression .

HY-W748591R

Cannflavin A (Standard)	Apoptosis Amyloid-β	Cancer
Cannflavin A (Standard) is the analytical standard of Cannflavin A. This product is intended for research and analytical applications. Cannflavin A can be isolated from Cannabis sativa L. Cannflavin A has anti-cancer, neuroprotective and anti-inflammatory activity. Cannflavin A inhibits Aβ1-42 aggregation. Cannflavin A also inhibits kynurenine-3-monooxygenase (KMO). Cannflavin A activates apoptosis via caspase-3 cleavage .

HY-P1378A

β-Amyloid (1-43)(human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) TFA is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) TFA shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) TFA could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use .

Cat. No.	Product Name	Target	Research Area

HY-P4886A

Amyloid β-Protein (3-42) TFA	Amyloid-β	Neurological Disease
Amyloid β-Protein (3-42) TFA is a precursor of Pyr peptide. Pyroglutamic acid-modified Aβ (pEAβ) (3-42) is the core of the amyloid plaque in Alzheimer's disease. pEAβ (3-42) accelerates the aggregation of Aβ(1-42), while Aβ(1-42) significantly slows down the primary and secondary nucleation of pEAβ(3-42).

HY-P1051A

β-Amyloid (12-28) (TFA) Amyloid β-Protein (12-28) (TFA); Amyloid Beta-Peptide (12-28) (human) TFA; β-Amyloid protein fragment(12-28) TFA	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (TFA) (Amyloid β-Protein (12-28) (TFA)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) (TFA) shows aggregation properties. β-Amyloid (12-28) (TFA) has the potential for Alzheimer’s disease research .

HY-P3908

FITC-β-Ala-Amyloid β-Protein (1-42) (ammonium)	Amyloid-β	Neurological Disease
FITC-β-Ala-Amyloid β-Protein (1-42) ammonium is a FITC tagged Aβ1-42 monomer peptide. Aβ1-42 plays a key role in the pathogenesis of Alzheimer’s disease .

HY-P4886

Amyloid β-Protein (3-42)	Amyloid-β	Neurological Disease
Amyloid β-Protein (3-42) is the precursor of Pyr peptide. Pyroglutamate-modified Aβ (pEAβ) (3-42) is the core of the amyloid template block in Alzheimer's disease. pEAβ(3-42) accelerated the aggregation of Aβ(1-42), while Aβ(1-42) significantly slowed the primary and secondary nucleation of pEAβ(3-42) .

HY-P1051

β-Amyloid (12-28) Amyloid β-Protein (12-28)	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research .

HY-P1787

β-Amyloid (4-10)	Amyloid-β	Neurological Disease
β-Amyloid (4-10) is an epitope for the polyclonal anti-Aβ(1-42) antibody, reduces amyloid deposition in a transgenic Alzheimer disease mouse model .

HY-P1060

LPYFD-NH2	Amyloid-β	Neurological Disease
LPYFD-NH2, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 can be used for the research of Alzheimer’s disease .

HY-P1060A

LPYFD-NH2 TFA	Amyloid-β	Neurological Disease
LPYFD-NH2 TFA, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 TFA can be used for the research of Alzheimer’s disease .

HY-P10578

SEN 304	Amyloid-β	Neurological Disease
SEN 304 is an Aβ aggregation inhibitor. SEN 304 can bind directly to Aβ(1-42), delay β-sheet formation and promote aggregation of toxic oligomers into a nontoxic form. SEN 304 can be used for research of Alzheimer’s disease .

HY-P10630

Pep63	Amyloid-β	Neurological Disease
Pep63 is a neuroprotective peptide (VFQVRARTVA). Pep63 has a neuroprotective effect on synaptic plasticity and memory. Pep63 can competitively bind with Aβ1-42 oligomers, and can block Aβ fiber formation. Pep63 can be used for Alzheimer’s disease (AD) research .

HY-P3860

Biotinyl-Amyloid β-Protein (1-42) (ammonium)	Amyloid-β	Neurological Disease
Biotinyl-Amyloid β-Protein (1-42) ammonium is a biotinylated Amyloid β-Protein (1-42) (HY-P1363). Biotinyl-Amyloid β-Protein (1-42) ammonium can be used for the research of Aβ1-42 converts to Aβ1-40 in brain .

HY-P10823

RI-OR2	Amyloid-β	Neurological Disease
RI-OR2, a retro-inverso peptide, is an amyloid-β (Aβ) oligomerization inhibitor. RI-OR2 binds to immobilized β-Amyloid (1-42) (HY-P1363A) monomers and fibrils, with an apparent K_d of 9-12 μM, and also acted as an inhibitor of Aβ(1-42) fibril extension .

HY-P1378A

β-Amyloid (1-43)(human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) TFA is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) TFA shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) TFA could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use .

HY-P1378

β-Amyloid (1-43)(human)	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use .

HY-P5905

*Citrullinated amyloid-β (1-42) peptide (human)* 1 Publications Verification Citrullinated Aβ (1-42); Citrullinated Aβ42	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .

HY-P4391

(Asp37)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Asp37)-Amyloid β-Protein (1-42) is the G37D mutant of wild-type Amyloid-beta (1-42) peptide .

HY-P5370

Scrambled β-amyloid (1-40)	Amyloid-β	Others
Scrambled β-amyloid (1-40) is a biological active peptide. (Aβ (1-40) together with Aβ (1-42) are two major C-terminal variants of the Aβ protein constituting the majority of Aβs. These undergo post-secretory aggregation and deposition in the Alzheimer’s disease brain. This peptide is the scrambled sequence of Abeta 1-40 HY-P0265)

HY-P5156

BDS-I	Potassium Channel	Neurological Disease
BDS-I known as blood depressing substance, is a marine toxin which can be extracted from Anemonia sulcata. BDS-I is a specific inhibitor of Potassium Channel, targeting to Kv3.4. BDS-I inhibits Aβ1-42-induced enhancement of KV3.4 activity, caspase-3 activation, and abnormal nuclear morphology of NGF-differentiated PC-12 cells. BDS-I reverts the Aβ peptide-induced cell death .

HY-P2712

Chemerin-9, mouse Chemerin148–156, mouse	Chemerin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Chemerin-9, mouse (Chemerin148-156, mouse) is a C-terminal nonapeptide of chemerin. Chemerin-9, mouse is a ligand for ChemR23 (EC₅₀ = 42 nM). Chemerin-9, mouse reduces basal lipolysis in primary mouse white adipocytes(IC₅₀ = 3.3 nM). Chemerin-9, mouse enhances memory and relieves Aβ1-42-induced memory impairment in AD mice. Chemerin-9, mouse also inhibits atherogenesis .

HY-P1844

Chemerin-9 (149-157)	Chemerin Receptor Akt ERK Reactive Oxygen Species Amyloid-β	Inflammation/Immunology
Chemerin-9 (149-157) is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) has anti-inflammatory activity. Chemerin-9 (149-157) stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) ameliorates Aβ_1-42-induced memory impairmen. Chemerin-9 (149-157) regulates immune responses, adipocyte differentiation, and glucose metabolism .

HY-P1844A

Chemerin-9 (149-157) (TFA) 4 Publications Verification	Chemerin Receptor Akt ERK Reactive Oxygen Species Amyloid-β	Inflammation/Immunology
Chemerin-9 (149-157) TFA is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) TFA has anti-inflammatory activity. Chemerin-9 (149-157) TFA stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) TFA ameliorates Aβ_1-42-induced memory impairmen. Chemerin-9 (149-157) TFA regulates immune responses, adipocyte differentiation, and glucose metabolism .

Cat. No.	Product Name		Classification

HY-146314

MAO-B-IN-9		Alkynes
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent MAO-B (monoamine oxidase B) inhibitor, with an IC₅₀ of 0.18 μM. MAO-B-IN-9 prevents Aβ_1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ_1-42 anti-aggregation effects . MAO-B-IN-9 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-16361A

Omigapil maleate CGP3466B; CGP3446 maleate; TCH346 maleate		Alkynes
Omigapil maleate, an orally bioavailable GAPDH nitrosylation inhibitor, abrogates Aβ_1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease . Omigapil maleate (CGP3446B maleate) is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD) . Omigapil (maleate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Aβ1-42

Inhibitors & Agonists

Peptides

NaturalProducts

Click Chemistry

Natural
Products